A Phase 2 Multi-Center Study Evaluating The Safety And Efficacy Of CD30-Directed Genetically Modified Autologous T Cells (CD30.CAR-T) In Adult And Pediatric Patients With Relapsed Or Refractory CD30 Positive Classical Hodgkin Lymphoma (CHARIOT TESSCAR001)